Internalization of the Hm1 muscarinic cholinergic receptor involves the third cytoplasmic loop  by Maeda, Sadaaki et al.
Volume 269, number 2 386-388 FEBS 08796 September 1990 
Internalization of the Hm 1 muscarinic holinergic receptor involves 
the third cytoplasmic loop 
Sadaaki Maeda’*, Jelveh Lamehl, William G. Mallet’, Mohan Philipz, J. Ramachandran2 and 
Wolfgang SadCel 
‘School of Pharmacy, University of California San Francisco, CA 94143, USA and =Neurex Corporation, 3760 Haven Avenue, 
Menlo Park, CA 94025, USA 
Received 22 June 1990 
The ml muscarinic receptor was previously shown to stimulate phosphatidyl inositol (PI) turnover and to internalize rapidly upon agonist activa- 
tion. Three receptor mutants with large deletions of the third cytoplasmic loop (i3) of human Hml, leaving only 11 and 8 amino acids at the amino 
and carboxy terminal junctions of i3, respectively, retained full ability to stimulate PI turnover, when expressed in U293 cells, but receptor intemali- 
xation was greatly reduced in two mutants with deletions reaching close to the NH, terminal of i3. We propose that a receptor domain located 
toward the amino terminal junction of i3 plays a role in Hml internalization. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The muscarinic cholinergic receptors belong to the 
family of Cl protein coupled receptors and contain a 
large third intracellular loop (i3) [ 1,2]. The i3 loops of 
ml and m2 direct the specificity of G protein coupling 
along different pathways [3], and preliminary results in- 
dicate that the i3 junctions adjacent to transmembrane 
domains 5 and 6 (TMD 5 and 6) are responsible for G 
protein coupling [4], as previously demonstrated for the 
adrenergic receptors (e.g. [5]). However, any other 
functions of the muscarinic i3 loop remained to be 
studied. Cholinergic agonists cause rapid internaliza- 
tion of ml and m3 [6-81, which are coupled to 
phosphatidyl inositol (PI) turnover [ 1,2]. Recently, 
Shapiro and Nathanson [9] have demonstrated that 
75% of the i3 loop of the mouse ml receptor can be 
deleted without affecting coupling to PI turnover and 
rapid receptor internalization, although the slower ml 
receptor downregulation was defective. Because of the 
large size of the i3 loop (208-366) the remaining 25% of 
i3 may contain important receptor functions. In the 
present study, we have constructed mutants of the 
human ml (Hml) receptor with large deletions in the i3 
loop and tested their ability to stimulate PI turnover 
and to internalize upon agonist activation. 
2.1. Construction of vectors expressing Hml and deletion 
mutants 
The gene encoding for Hml was obtained from a human placental 
genomic DNA library in vector EMBW (from Clontech Labs, Palo 
Alto, CA), using a specific oligonucleotide probe, followed by 
amplification of the coding sequence with the polymerase chain reac- 
tion [lo] using two oligonucleotide primers immediately adjacent to 
the start and stop codons of the Hml gene. The amplified gene pro- 
duct was then cloned into pGemTM - 3 (Promega, Madison, WI), us- 
ing the Sma-I restriction site, and subsequently transferred into the 
mammalian expression vector pSGS (Stratagene, La Jolla, CA). 
Restriction fragments were subcloned into ml3 and sequenced using 
the Applied Biosciences Automatic Sequencer. No deviations of the 
obtained sequence from the published sequence were observed within 
the coding frame which does not contain any introns [ 1.21. Deletions 
of the i3 domain were introduced, after cutting the Gem-3/Hml vec- 
tor with the unique Stu-I restriction site at position 812 (at codon for 
R-271). by digestion with the exonuclease Bal-31 for varying times at 
4°C. The blunt-ended product was then self-ligated. Mutants with 
deletions roughly equivalent in size to the i3 loop (from Y-208 to 
T-366) were selected, transferred to pSG5, using Bum HI and Eco RI, 
and expressed in human embryonic kidney U293 cells with the calcium 
phosphate precipitation method (21. Three clones which gave the 
desired deletion size and yielded productive muscarinic tracer binding 
upon transfection, were sequenced and termed d219-333, d220-349 
and d232-358. to indicate the deleted amino acid sequences. None of 
the three mutants contained a new amino acid at the ligation junc- 
tions. 
2.2. Trat&@ction, receptor binding, and PI turnover 
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HMl and the deletion mutants, placed in pSG5, were transfected (6 
pg DNA), using the calcium phosphate precipitation method, into 
U293 [2] cells plated out in 10 mm plastic Petri dishes. After 2 days 
incubation, muscarinic receptor density rose from a background of 
< 30 fmol/mg protein to over 1000 fmol/mg protein. Cells were then 
brought into suspension with PBS/EDTA, washed, and replated into 
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6 well tissue culture plates. After 2 h at 37”C, the cells had reattached 
and receptor binding assays were then performed with either cell 
homogenates (to determine [‘HINMS saturation or carbachol 
displacement curves f GppNHp) or with the intact cells according to 
the method of Liles et al. [6]. In order to assess receptor intemaliza- 
tion, the intact cells were pretreated with 1 mM carbachol or 100 nM 
phorbol 12-myristate 13-acetate @MA)/300 nM A23187 [a], for 
either 30 min or 2 h immediately prior to the receptor assay. For 
ligand displacement studies, 0.1 nM N [3H]methylscopolamine 
(fH]NMS) was used, whereas for the internalization assay, 1 .O nM 
[ H]NMS was used. The higher tracer concentration produces a large 
degree of receptor saturation, and the total tracer binding was taken 
to approximate receptor density for the wild-type Hml receptor. 
Phosphatidyl inositol (PI) turnover was measured by the method of 
Berridge et al. [1 l] after labeling of the cells with ‘H-inositol for 24 h. 
3. RESULTS AND DISCUSSION 
Expression of the cloned Hml gene, using pSG5, 
gave abundant ‘H-NMS binding in transiently 
transfected U293 cells (3042 -I 413 fmol/mg protein 
(n = 10) over a background of 9-15 fmol/mg protein in 
nontransfected cells. The Kd for NMS of 0.14 nM is 
consistent with previous results [6]. Further, carbachol 
displaced t3H]NMS with an ICSO of 0.4 mM in mem- 
brane homogenates, and its affinity was not affected by 
the presence of 100 pM GppNHp. Lack of guanyl 
nucleotide effects on carbachol binding to ml is also 
consistent with earlier reports [9,12], and it is not in- 
dicative of failure to couple to G proteins. The ECSO 
value for carbachol in stimulating PI turnover was ap- 
proximately 20 ,uM, and 1 mM carbachol produced 
maximum effect. Using lower amounts of plasmid 
DNA for transfection to vary ml receptor expression in 
U293 cells, it was found that 1 mM carbachol produced 
maximum stimulation when receptor density exceeded 
300-500 fmol per mg protein. Among a large number of 
Hml deletion mutants, three were selected that gave 
comparable [3H]NMS binding upon transfection of 
U293 cells (bound after incubation with 1 nM [‘H]NMS 
in fmol/mg protein: 1412 f 251 (d219-333), 1783 f 
442 (d220-349), and 2385 f 484 (d232-350), n= 10). 
t3H]NMS equilibrium binding curves, performed with 
cell membranes transfected with d220-d349 and 
d232-358 gave the following respective values: I& 0.2 
mM and 1.8 mM for carbachol and Kd 3.5 nM and 2.1 
nM for NMS. Hence, both mutants displayed a 10 to 
20-fold lower affinity for the antagonist NMS, while 
the carbachol affinity of d232-358 was 5-fold lower and 
that of d220-349 2-fold higher than in the wild-type. 
These results indicate some limited changes in overall 
receptor structure caused by the large deletions. Fur- 
ther, because of the lower affinity of NMS, the total 
number of expressed binding sites, estimated on the 
basis of the 1 nM ‘H-NMS incubations, is approximate- 
ly 2 to 3-fold higher for d220-349 and d232-358 than 
for the wild-type receptor. Smaller deletions involving 
amino acids 221 to 343 [9] of the mouse ml receptor 
were previously shown not to affect agonist or an- 
tagonist receptor binding. A carbachol dose response 
Table I 
Stimulation of PI turnover by 1 mM carbachol. 
Vo of control SE (n = 3-4) 
U293 native 247 34 
Hml 1831 241 
d219-333 2555 708 
d220-349 1835 340 
d232-358 2214 491 
Cells were pretreated with [“Hlinositol and IP, IPI and IP3 release was 
measured as percent of control (no carbachol). The percent increases 
for IP, IP2 and IPs were averaged. Receptor density was measured 
simultaneously in one experiment and was similar in Hml undeleted 
and mutant transfected cells. Baseline release levels of IP, IPr and IP3 
averaged 10,514 f 3,404,520 f 323 and437 f 201 dpm, respectively 
(n = 22). 
curve for d232-350 (PI turnover) gave an EC50 value of 
approximately 50 PM, a 2.5-fold shift from the wild- 
type (- 20 PM), but 1 mM carbachol still yielded max- 
imum stimulation of PI turnover. On the basis of this 
result, we compared the ability of ml and the three dele- 
tion mutants to increase PI turnover when stimulated 
with 1 mM carbachol. Although the deletions range 
from positions 219 to 358, and thus, span most of the 
i3 loop (208 to 366), all three mutants were as effective 
as the undeleted Hml in stimulating PI turnover (Table 
I). This result limits the regions of i3 that can be involv- 
ed with coupling to G proteins to 11 and 8 amino acids 
at the amino and carboxy terminal junctions of i3, 
respectively, whereas the large remainder of i3 does not 
appear to affect strongly the coupling process. 
Upon pretreatment of the transfected cells with car- 
bachol, rapid internalization was observed with the 
quarternary tracer [3H]NMS which does not penetrate 
the intact cells [6] (Fig. 1). The process was complete at 
30 min pretreatment and did not continue beyond 55% 
F 
I30 m,n Carb 
100 
2 h Carb 
d 219-333 
Fig. 1. Loss of surface ‘H-NMS binding sites upon preincubation of 
transfected U293 cells with 1 mM carbachol (A). *Significantly 
different when compared to preincubated wild-type Hml, P c 0.05. 
Student t-test (a = 4), except for the value for d219-333 at 30 min, 
where n = 3). 
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internalization at 2 h. In contrast, no measurable inter- 
nalization occurred with mutant d232-358 which con- 
tains the deletion closest to the carboxy terminal junc- 
tion of i3. Mutant d220-349 measurably internalized 
only after 2 h carbachol pretreatment, whereas 
d219-333 showed some internalization already at 30 
min and was not significantly different from the wild- 
type at 2 h. These results implicate the region from 
R334 to V358 of Hml as playing a role in receptor inter- 
nalization. Since rapid internalization of a mouse ml 
mutant with deletion to position 343 was also unaf- 
fected [9], this region may be further narrowed to R344 
to V358, containing two potential phosphorylation con- 
sensus sites (T384 and S356). However, the large dele- 
tions of d220-349 and d232-358 had a small but 
measurable effect on overall receptor structure, and 
more of these mutants receptors were expressed at the 
cell surface than for the wild-type receptor. While the 
latter result is consistent with an impaired receptor in- 
ternalization pathway, point mutations are now re- 
quired to pinpoint the receptor domain responsible for 
rapid internalization upon agonist exposure. 
Acknowledgement: This work was supported by a US Public Health 
Research Grant, GM43102, from the NIH General Medical Sciences. 
REFERENCES 
111 
PI 
[31 
[41 
PI 
b51 
171 
PI 
191 
HOI 
[ill 
WI 
Bonner, T.I. (1989) Trends Neurol. Sci., 12, 148-151. 
Peralta, E.G., Ashkenazi, A., Winslow, J.W., Smith, D.H., 
Ramachandran, J. and Capon, D.J. (1987) EMBO J. 6, 
3923-3929. 
Kubo, T., Bujo, H., Akiba, I., Nakai, J.. Mishina, M. and 
Numa, S. (1988) FEBS Lett. 241, 119-125. 
Bonner, T.I. (1989) Trends Pharmacol. Sci. Suppl. Subtypes of 
Muscarinic Receptor IV, pp. 11-15. 
Strader, C.D., Dixon, R.A.T., Cheung, A.H., Candelore, 
M.R., Blake, A.D. and Sigal, I.S. (1987) J. Biol. Chem. 262, 
16439-16443. 
Liles, W.C., Hunter, D.D. Meier, K.E., Nathanson, N.M. 
(1986) J. Biol. Chem. 261, 5307-5313. 
El-Fakahany, E.E. and Lee, J.-H. (1986) Eur. J. Pharmacol. 
132, 31-30. 
Fisher, S.-K. (1988) Mol. Pharmacol. 33, 414-422. 
Shapiro, R.A. and Nathanson, N.M. (1989) B&hem. 28, 
89468950. 
Saiki, K.S., Gelfand, D.H., Stoffel, S., Scharf, S.J., Higuchi, 
R., Horn, G.T., Mullis, K.B., Erlich, H.A. (1988) Science 239, 
487-494. 
Berridge, M.J., Downes, C.P., and Hanley, M.R. (1982) 
Biochem. J. 206, 587-595. 
Nathanson, N.M. (1987) Annu. Rev. Neurosci. 10, 195-236. 
388 
